Developer docs
API playgroundTry for free, no card

Search company profiles

Frontier Medicines

Full company profile

uuid0000feg

Namestring
Frontier Medicines
Legal namestring
Frontier Medicines Corporation
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Frontier Medicines is a clinical-stage biopharmaceutical company developing covalent small-molecule precision medicines against protein targets historically considered undruggable, with an initial focus on oncology. The company's core technology is the proprietary Frontier™ Platform, which integrates chemoproteomics, covalent chemistry, and artificial intelligence (CovalentAI™) to map more than 150,000 covalent binding sites across the human proteome and identify actionable ligands for over 8,000 targets. Built on a proprietary Covalent Ground Truth (CoGT™) dataset of more than 2 billion data points, the platform claims to advance clinical candidates in 1.5–2 years versus 3–5 years for conventional methods. Frontier's pipeline includes FMC-376, a dual ON+OFF KRAS G12C inhibitor in Phase 1/2 clinical trials (PROSPER trial); FMC-242, a covalent PI3Kα-RAS breaker in IND-enabling stage; and FMC-220, a covalent p53 Y220C activator licensed to LG Chem for development outside Greater China. The company also maintains a global strategic collaboration with AbbVie covering E3 ligases and certain oncology and immunology targets.

Frontier is headquartered in South San Francisco with a second research facility in Boston. It was founded in 2019 by Chris Varma, Ph.D. (former Blueprint Medicines CEO), Daniel K. Nomura, Ph.D., and Roberto Zoncu, Ph.D., both UC Berkeley faculty. The company has raised approximately $335.5 million in private funding across Series A ($67M, 2019), Series B ($88.5M, 2021), and Series C ($100M total, 2024) financing rounds from investors including Deerfield Management, Droia Ventures, MPM Capital, RA Capital Management, and Woodline Partners LP.

The business model is asset-light in commercial terms: Frontier generates revenue through pharmaceutical partnership upfronts, R&D reimbursements, milestone payments, and royalties rather than direct product sales, as no candidates are yet approved. The AbbVie partnership provides $55 million in upfront cash and eligibility for milestones exceeding $1 billion plus royalties; the LG Chem license for FMC-220 generates near-term development capital while Frontier retains Greater China commercial rights. Customers are exclusively enterprise pharmaceutical counterparties (AbbVie, LG Chem). End-user "customers" are oncology patients with KRAS-mutated, p53-mutated, and PI3Kα/RAS-pathway-altered cancers, though these are not direct purchasers.

Short descriptiontext

Frontier Medicines is a clinical-stage biopharmaceutical company developing covalent small-molecule precision medicines against previously undruggable cancer targets, using its proprietary chemoproteomics- and AI-powered Frontier™ Platform. It serves oncology patients via three pipeline programs and enterprise partners including AbbVie and LG Chem.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
covalent drug discovery, precision oncology therapeutics, chemoproteomics platform, small molecule drugs, targeted protein degradation
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and licensing revenue
TypeLicensing Royalties
Description

Frontier Medicines generates revenue through strategic partnerships with pharmaceutical companies. They receive upfront payments, R&D reimbursements, milestone payments, and royalty payments on commercialized products. Example: AbbVie partnership with $55 million upfront, potential milestone payments exceeding $1 billion, plus royalties. LG Chem licensing deal for FMC-220 with development and commercialization rights.

frontiermeds.com
2Drug development and commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Frontier develops its proprietary pipeline of precision medicines through clinical trials with the goal of commercializing drugs. FMC-376 is in Phase 1/2 clinical trials (PROSPER trial). Revenue will be generated from future drug sales upon regulatory approval.

frontiermeds.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1The Frontier™ Platform
Description

Proprietary platform powered by chemoproteomics, covalent chemistry, and artificial intelligence for drug discovery.

frontiermeds.com
+2 more records
Core offering1 text field

Frontier Medicines is a clinical-stage biopharmaceutical company that develops small molecule covalent drugs against previously undruggable disease-causing protein targets, primarily in oncology. Its proprietary Frontier Platform combines chemoproteomics, covalent chemistry, and artificial intelligence to discover covalent binding sites, identify actionable ligands, and accelerate optimization to clinical candidates. The company has a pipeline of precision oncology drug candidates including FMC-376 (KRAS G12C), FMC-220 (p53 Y220C), and FMC-242 (PI3Kα-RAS).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Access to over 90% of human proteins vs. less than 10% with traditional methods
+5 more records
Product overview1 text field

Frontier Medicines is a precision medicine company developing a pipeline of small molecule drugs against previously undruggable cancer targets. The company's core offering is The Frontier™ Platform, a chemoproteomics and AI-powered covalent drug discovery system that enables identification of actionable binding sites across >90% of the human proteome. The platform comprises the Druggability Atlas™ (150,000+ covalent binding sites database), CovalentAI™ (AI-driven design engine), and an optimized covalent fragment library. The company's pipeline includes three named drug candidates: FMC-376 (dual KRAS G12C ON+OFF inhibitor in Phase 1/2 clinical trials), FMC-242 (PI3Kα-RAS breaker in IND-enabling stage), and FMC-220 (p53 Y220C activator licensed to LG Chem). The company also maintains a global partnership with AbbVie for E3 ligase and certain oncology/immunology targets.

Product and service3 records
1FMC-376
CategoryDrug candidate
Description

A first-in-class dual inhibitor targeting both ON (active) and OFF (inactive) states of KRAS G12C with exquisite selectivity, designed to overcome resistance seen with single-acting KRAS G12C treatments in NSCLC, colorectal carcinoma, and pancreatic cancer patients.

2FMC-220
CategoryDrug candidate
Description

A first-in-class covalent activator of p53 Y220C designed to selectively restore p53 tumor suppressor function for solid tumor cancers with TP53 Y220C mutations (including ovarian, lung, breast, colorectal cancers). Licensed to LG Chem for worldwide development and commercialization outside Greater China.

3FMC-242
CategoryDrug candidate
Description

A covalent allosteric inhibitor that breaks the PI3Kα-RAS interaction to inhibit downstream tumor signaling without impacting normal functions such as glucose homeostasis. Designed for lung, colorectal, and breast cancer patients as single agent or in combination with KRAS inhibitors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1LG Chem
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-31
Description

Exclusive worldwide licensing agreement (outside of Greater China) for FMC-220, a first-in-class covalent p53 Y220C activator for solid tumor cancers. LG Chem leads regulatory, clinical, and commercial activities in their territories. Frontier retains full ownership within Greater China.

biospace.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-12-02
Description

Global strategic collaboration to discover, develop and commercialize small molecule therapeutics against novel E3 ligases and certain oncology and immunology targets. AbbVie pays $55M upfront, reimburses R&D costs, and Frontier is eligible for milestones exceeding $1B plus royalties. AbbVie leads global development and commercialization; Frontier retains option to share development expenses for certain oncology programs through Phase 2.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing covalent inhibitors of difficult-to-drug targets including RAS(ON) inhibitors. Closest direct competitor to Frontier given overlapping focus on covalent chemistry against historically undruggable oncology targets, particularly in the RAS/MAPK pathway.

TypeDirect peer
Description

Developed Krazati (adagrasib), a KRAS G12C inhibitor competing directly with Frontier's FMC-376 in the same indication. Acquired by Bristol-Myers Squibb in 2024, Mirati represents the competitive benchmark Frontier's dual ON+OFF mechanism must beat in NSCLC, CRC, and other KRAS G12C-driven tumors.

TypeDirect peer
Description

Precision oncology company using its proprietary platform to discover small molecule kinase inhibitors against allosteric and mutant-specific targets. Compares to Frontier in its platform-driven approach to historically undruggable oncology targets and similar clinical-stage positioning.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology, chemistry, and machine learning at scale. Peer to Frontier's CovalentAI platform approach, though broader in modality and indication scope; both are technology-led discovery companies seeking to industrialize early-stage drug creation.

TypeDirect peer
Description

Computational drug discovery platform combining physics-based simulation with machine learning to accelerate small molecule discovery. Comparable to Frontier as a platform-company leveraging computation/AI for early-stage drug discovery, though Schrödinger's platform is modality-agnostic vs. Frontier's covalent focus.

TypeDirect peer
Description

Clinical-stage biotechnology company pioneering targeted protein degradation (PROTAC) using E3 ligase technology. Direct relevance because Frontier's AbbVie collaboration is also focused on E3 ligases, making Arvinas a peer in the same target class and partnership ecosystem.

TypeDirect peer
Description

Clinical-stage precision oncology company developing medicines against previously undruggable targets in chromatin biology using its Gene Traffic Control platform. Comparable to Frontier in its platform-driven approach to historically difficult targets and clinical-stage development focus.

TypeEmerging player
Description

Clinical-stage precision oncology company focused on the RAS/MAPK pathway with multiple programs targeting KRAS and downstream nodes. Relevant peer in the oncology indication overlap, particularly for KRAS G12C and PI3K/RAS pathway programs where Frontier also competes.

TypeEmerging player
Description

AI-driven drug discovery company combining high-throughput biology, machine learning, and chemistry to discover new medicines. Adjacent peer to Frontier in AI-enabled discovery, though Insitro focuses on phenotypic data and broader modalities vs. Frontier's covalent chemistry specialization.

TypeBroad incumbent
Description

Large biopharmaceutical company and first-to-market with Lumakras (sotorasib), a KRAS G12C inhibitor approved in NSCLC. Represents the incumbent benchmark Frontier's FMC-376 dual mechanism aims to differentiate against, though Amgen's broader portfolio means KRAS is one of many programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frontier Medicines

Precision Oncology Therapeuticsfrontiermeds.com

Frontier Medicines is a clinical-stage biopharmaceutical company developing covalent small-molecule precision medicines against previously undruggable cancer targets, using its proprietary chemoproteomics- and AI-powered Frontier™ Platform. It serves oncology patients via three pipeline programs and enterprise partners including AbbVie and LG Chem.

What Frontier Medicines does

Frontier Medicines is a clinical-stage biopharmaceutical company developing covalent small-molecule precision medicines against protein targets historically considered undruggable, with an initial focus on oncology. The company's core technology is the proprietary Frontier™ Platform, which integrates chemoproteomics, covalent chemistry, and artificial intelligence (CovalentAI™) to map more than 150,000 covalent binding sites across the human proteome and identify actionable ligands for over 8,000 targets. Built on a proprietary Covalent Ground Truth (CoGT™) dataset of more than 2 billion data points, the platform claims to advance clinical candidates in 1.5–2 years versus 3–5 years for conventional methods. Frontier's pipeline includes FMC-376, a dual ON+OFF KRAS G12C inhibitor in Phase 1/2 clinical trials (PROSPER trial); FMC-242, a covalent PI3Kα-RAS breaker in IND-enabling stage; and FMC-220, a covalent p53 Y220C activator licensed to LG Chem for development outside Greater China. The company also maintains a global strategic collaboration with AbbVie covering E3 ligases and certain oncology and immunology targets.

Frontier is headquartered in South San Francisco with a second research facility in Boston. It was founded in 2019 by Chris Varma, Ph.D. (former Blueprint Medicines CEO), Daniel K. Nomura, Ph.D., and Roberto Zoncu, Ph.D., both UC Berkeley faculty. The company has raised approximately $335.5 million in private funding across Series A ($67M, 2019), Series B ($88.5M, 2021), and Series C ($100M total, 2024) financing rounds from investors including Deerfield Management, Droia Ventures, MPM Capital, RA Capital Management, and Woodline Partners LP.

The business model is asset-light in commercial terms: Frontier generates revenue through pharmaceutical partnership upfronts, R&D reimbursements, milestone payments, and royalties rather than direct product sales, as no candidates are yet approved. The AbbVie partnership provides $55 million in upfront cash and eligibility for milestones exceeding $1 billion plus royalties; the LG Chem license for FMC-220 generates near-term development capital while Frontier retains Greater China commercial rights. Customers are exclusively enterprise pharmaceutical counterparties (AbbVie, LG Chem). End-user "customers" are oncology patients with KRAS-mutated, p53-mutated, and PI3Kα/RAS-pathway-altered cancers, though these are not direct purchasers.

Frontier Medicines firmographics

Firmographics
Name
Frontier Medicines
Legal name
Frontier Medicines Corporation
Website
https://frontiermeds.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Frontier Medicines is a clinical-stage biopharmaceutical company developing covalent small-molecule precision medicines against previously undruggable cancer targets, using its proprietary chemoproteomics- and AI-powered Frontier™ Platform. It serves oncology patients via three pipeline programs and enterprise partners including AbbVie and LG Chem.
Ownership category
akta.pro rank

Frontier Medicines industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Covalent drug discovery
  • Precision oncology therapeutics
  • Chemoproteomics platform
  • Small molecule drugs
  • Targeted protein degradation

Where Frontier Medicines is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Frontier Medicines business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership and licensing revenue: Frontier Medicines generates revenue through strategic partnerships with pharmaceutical companies. They receive upfront payments, R&D reimbursements, milestone payments, and royalty payments on commercialized products. Example: AbbVie partnership with $55 million upfront, potential milestone payments exceeding $1 billion, plus royalties. LG Chem licensing deal for FMC-220 with development and commercialization rights.
  2. Drug development and commercialization: As a clinical-stage biopharmaceutical company, Frontier develops its proprietary pipeline of precision medicines through clinical trials with the goal of commercializing drugs. FMC-376 is in Phase 1/2 clinical trials (PROSPER trial). Revenue will be generated from future drug sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Frontier Medicines product offering

Product offering

Core offering

Frontier Medicines is a clinical-stage biopharmaceutical company that develops small molecule covalent drugs against previously undruggable disease-causing protein targets, primarily in oncology. Its proprietary Frontier Platform combines chemoproteomics, covalent chemistry, and artificial intelligence to discover covalent binding sites, identify actionable ligands, and accelerate optimization to clinical candidates. The company has a pipeline of precision oncology drug candidates including FMC-376 (KRAS G12C), FMC-220 (p53 Y220C), and FMC-242 (PI3Kα-RAS).

Product overview

Frontier Medicines is a precision medicine company developing a pipeline of small molecule drugs against previously undruggable cancer targets. The company's core offering is The Frontier™ Platform, a chemoproteomics and AI-powered covalent drug discovery system that enables identification of actionable binding sites across >90% of the human proteome. The platform comprises the Druggability Atlas™ (150,000+ covalent binding sites database), CovalentAI™ (AI-driven design engine), and an optimized covalent fragment library. The company's pipeline includes three named drug candidates: FMC-376 (dual KRAS G12C ON+OFF inhibitor in Phase 1/2 clinical trials), FMC-242 (PI3Kα-RAS breaker in IND-enabling stage), and FMC-220 (p53 Y220C activator licensed to LG Chem). The company also maintains a global partnership with AbbVie for E3 ligase and certain oncology/immunology targets.

Differentiator

Problem solved

Functional benefit

Brands

  • The Frontier™ Platform: Proprietary platform powered by chemoproteomics, covalent chemistry, and artificial intelligence for drug discovery.
  • Druggability Atlas™
  • CovalentAI™

Products and services

  • FMC-376 A first-in-class dual inhibitor targeting both ON (active) and OFF (inactive) states of KRAS G12C with exquisite selectivity, designed to overcome resistance seen with single-acting KRAS G12C treatments in NSCLC, colorectal carcinoma, and pancreatic cancer patients.
  • FMC-220 A first-in-class covalent activator of p53 Y220C designed to selectively restore p53 tumor suppressor function for solid tumor cancers with TP53 Y220C mutations (including ovarian, lung, breast, colorectal cancers). Licensed to LG Chem for worldwide development and commercialization outside Greater China.
  • FMC-242 A covalent allosteric inhibitor that breaks the PI3Kα-RAS interaction to inhibit downstream tumor signaling without impacting normal functions such as glucose homeostasis. Designed for lung, colorectal, and breast cancer patients as single agent or in combination with KRAS inhibitors.

Quantifiable outcome

  • Access to over 90% of human proteins vs. less than 10% with traditional methods
  • +5 more outcomes

Companies that use Frontier Medicines

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Frontier Medicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Frontier Medicines partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • LG ChemcoreOEM/ Whitelabel/ Licensing Partner · 31 March 2026Exclusive worldwide licensing agreement (outside of Greater China) for FMC-220, a first-in-class covalent p53 Y220C activator for solid tumor cancers. LG Chem leads regulatory, clinical, and commercial activities in their territories. Frontier retains full ownership within Greater China.
  • AbbVieflagshipStrategic or Co-development Partner · 2 December 2020Global strategic collaboration to discover, develop and commercialize small molecule therapeutics against novel E3 ligases and certain oncology and immunology targets. AbbVie pays $55M upfront, reimburses R&D costs, and Frontier is eligible for milestones exceeding $1B plus royalties. AbbVie leads global development and commercialization; Frontier retains option to share development expenses for certain oncology programs through Phase 2.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Frontier Medicines competitors and assessment

Company assessment

Direct peers

  • Revolution Medicines: Clinical-stage precision oncology company developing covalent inhibitors of difficult-to-drug targets including RAS(ON) inhibitors. Closest direct competitor to Frontier given overlapping focus on covalent chemistry against historically undruggable oncology targets, particularly in the RAS/MAPK pathway.
  • Mirati Therapeutics: Developed Krazati (adagrasib), a KRAS G12C inhibitor competing directly with Frontier's FMC-376 in the same indication. Acquired by Bristol-Myers Squibb in 2024, Mirati represents the competitive benchmark Frontier's dual ON+OFF mechanism must beat in NSCLC, CRC, and other KRAS G12C-driven tumors.
  • Black Diamond Therapeutics: Precision oncology company using its proprietary platform to discover small molecule kinase inhibitors against allosteric and mutant-specific targets. Compares to Frontier in its platform-driven approach to historically undruggable oncology targets and similar clinical-stage positioning.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology, chemistry, and machine learning at scale. Peer to Frontier's CovalentAI platform approach, though broader in modality and indication scope; both are technology-led discovery companies seeking to industrialize early-stage drug creation.
  • Schrödinger Inc. Computational drug discovery platform combining physics-based simulation with machine learning to accelerate small molecule discovery. Comparable to Frontier as a platform-company leveraging computation/AI for early-stage drug discovery, though Schrödinger's platform is modality-agnostic vs. Frontier's covalent focus.
  • Arvinas: Clinical-stage biotechnology company pioneering targeted protein degradation (PROTAC) using E3 ligase technology. Direct relevance because Frontier's AbbVie collaboration is also focused on E3 ligases, making Arvinas a peer in the same target class and partnership ecosystem.
  • Foghorn Therapeutics: Clinical-stage precision oncology company developing medicines against previously undruggable targets in chromatin biology using its Gene Traffic Control platform. Comparable to Frontier in its platform-driven approach to historically difficult targets and clinical-stage development focus.

Emerging players

  • Erasca: Clinical-stage precision oncology company focused on the RAS/MAPK pathway with multiple programs targeting KRAS and downstream nodes. Relevant peer in the oncology indication overlap, particularly for KRAS G12C and PI3K/RAS pathway programs where Frontier also competes.
  • Insitro: AI-driven drug discovery company combining high-throughput biology, machine learning, and chemistry to discover new medicines. Adjacent peer to Frontier in AI-enabled discovery, though Insitro focuses on phenotypic data and broader modalities vs. Frontier's covalent chemistry specialization.

Broad incumbents

  • Amgen (Lumakras/sotorasib program): Large biopharmaceutical company and first-to-market with Lumakras (sotorasib), a KRAS G12C inhibitor approved in NSCLC. Represents the incumbent benchmark Frontier's FMC-376 dual mechanism aims to differentiate against, though Amgen's broader portfolio means KRAS is one of many programs.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Frontier Medicines social profiles

Digital presence

Frontier Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Frontier Medicines leadership team

Management profile

Number of profiles

Profiles17 records

Frontier Medicines funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Frontier Medicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frontier Medicines

What does Frontier Medicines do?

Frontier Medicines is a clinical-stage biopharmaceutical company that develops small molecule covalent drugs against previously undruggable disease-causing protein targets, primarily in oncology. Its proprietary Frontier Platform combines chemoproteomics, covalent chemistry, and artificial intelligence to discover covalent binding sites, identify actionable ligands, and accelerate optimization to clinical candidates. The company has a pipeline of precision oncology drug candidates including FMC-376 (KRAS G12C), FMC-220 (p53 Y220C), and FMC-242 (PI3Kα-RAS).

Is Frontier Medicines a public or private company?

Frontier Medicines is a private company. It is classified as venture growth investor backed and is currently operating.

When was Frontier Medicines founded?

Frontier Medicines was founded in 2019. It employs 51 to 100 people.

Where is Frontier Medicines based?

Frontier Medicines is headquartered in South San Francisco, United States, in the North America region.

How does Frontier Medicines make money?

Two revenue lines are on record. Partnership and licensing revenue is the primary driver. The others are drug development and commercialization.

Who are Frontier Medicines's main competitors?

Direct peers on record are Revolution Medicines, Mirati Therapeutics, Black Diamond Therapeutics, Recursion Pharmaceuticals, Schrödinger Inc., Arvinas and Foghorn Therapeutics. Emerging players are Erasca and Insitro. Amgen (Lumakras/sotorasib program) is listed as a broad incumbent.

Does Frontier Medicines have an API?

No public API is recorded for Frontier Medicines.

What industry is Frontier Medicines in?

Frontier Medicines's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogFrontier Medicines to Present Preclinical Data for FMC-242, a Novel Covalent Allosteric PI3Kα-RAS Breaker, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsFrontier Medicines will present preclinical data for FMC-242 at the 38th EORTC-NCI-AACR Symposium in Barcelona. The data show enhanced anti-tumor activity with KRAS inhibitors in KRAS-mutant models, and the FDA has allowed an IND for human trials. Phase 1/2 dosing is expected to begin in coming months.Seeking AlphaFrontier Medicines reports promising lung cancer drug results in early trialFrontier Medicines reported that its experimental lung cancer drug FMC-376 shrank tumors in 56% of evaluable patients in an early-stage trial. Among 18 patients with KRAS G12C mutations, 10 had confirmed tumor shrinkage, with a 67% response rate among nine never-treated patients and 44% among nine previously treated. Responses lasted a median of 7.5 months.TradingViewFrontier Medicines reports promising lung cancer drug results in early trialFrontier Medicines reported that its experimental lung cancer drug FMC-376 shrank tumors in 56% of evaluable patients in an early-stage trial. Among 18 patients, 10 had confirmed tumor shrinkage, with a 67% response rate among nine never-treated and 44% among nine previously treated. Responses lasted a median of 7.5 months, and nine of the 10 responders had additional resistance-associated genetic alterations.Business Wire BlogFrontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026Frontier Medicines presented Phase 1/2 PROSPER trial data for FMC-376, an equipotent KRAS G12C ON+OFF inhibitor, in KRAS G12C-mutant NSCLC at ESMO 2026. The 500 mg BID dose showed a 56% confirmed overall response rate, with a median duration of response of 7.5 months and a favorable hepatic safety profile. The trial is ongoing, including combination with pembrolizumab.FinancialContent Business PageFrontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026Frontier Medicines presented Phase 1/2 PROSPER trial data for FMC-376, a KRAS G12C ON+OFF inhibitor, at ESMO 2026. In 18 NSCLC patients, the drug achieved a 56% confirmed overall response rate, with 7.5 months median duration of response and a favorable hepatic safety profile. The trial is ongoing, including combination with pembrolizumab.Business Wire BlogFrontier Medicines to Present First Clinical Data for FMC-376, an Equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026Frontier Medicines will present preliminary clinical data from the Phase 1 portion of its PROSPER trial for FMC-376, a KRAS G12C ON+OFF inhibitor, at ESMO Congress 2026 in Madrid. The data report anti-tumor activity and tolerability in patients with advanced KRAS G12C-mutant solid tumors, including those previously treated with KRAS G12C inhibitors.FierceBiotechAfter some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platformFrontier Medicines CEO Chris Varma said the biotech is advancing more cancer drugs into the clinic after a February 2025 layoff announcement, with the number of employees let go not disclosed. The Boston-based company, with about 60 people, has raised $200 million from partnerships versus $250 million from investors. Varma aims to deliver roughly one new molecule into the clinic annually.BioSpaceFrontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of DirectorsFrontier Medicines appointed David R. Epstein to its board of directors. Epstein, currently CEO of Ottimo Pharma, previously led Seagen and Novartis, and brings over 30 years of drug development experience. He will support Frontier's pipeline of covalent precision medicines, including FMC-242 and FMC-376.BioSpaceFrontier Medicines Announces Exclusive Licensing Agreement for FMC-220, a First-in-Class Covalent p53 Y220C Activator, with LG Chem, Ltd.Frontier Medicines Corporation granted LG Chem, Ltd. an exclusive worldwide license to develop and commercialize FMC-220, a first-in-class covalent p53 Y220C activator for solid tumor cancers, outside of Greater China. Under the terms of the agreement, Frontier will receive an upfront payment plus potential clinical, regulatory, and commercial milestone payments, along with mid-single-digit to double-digit royalties on net sales. LG Chem will lead regulatory filings, global clinical development, manufacturing, and commercialization in the licensed territories, with Frontier retaining ownership and full control in Greater China.MorningstarFrontier Medicines to Present Findings on PI3Kα-RAS Breaker FMC-242 and AI-Powered Frontier™ Platform at AACR Annual Meeting 2026Frontier Medicines Corporation announced it will present preclinical data on its FMC-242 program and AI-powered Frontier™ Platform at the AACR Annual Meeting 2026 in San Diego. FMC-242 is a first-in-class allosteric breaker of the PI3Kα-RAS interaction demonstrating robust anti-tumor activity in preclinical models of HER2-amplified and KRAS-mutated cancers. The data shows the compound maintains favorable tolerability and enhances anti-tumor activity when combined with EGFR inhibitors, KRASG12C inhibitors, and pan-RAS/KRAS agents.